D., President and CEO of Aeterna Zentaris mentioned, ‘We are very happy with AEZS-108 gaining orphan-medication designation for ovarian tumor from the FDA since it would provide it with extra market exclusivity protection. We look forward to reporting the final results from our ongoing European Stage 2 study in ovarian and endometrial malignancy, later this year.’.. Aeterna Zentaris granted FDA orphan-drug designation for AEZS-108 in ovarian cancer Aeterna Zentaris Inc. , a late-stage drug development company specific in oncology and endocrinology, today announced that it has received from the U.S. Food and Drug Administration , orphan-medication designation for AEZS-108, its doxorubicin targeted conjugate substance, for the treatment of ovarian cancer. AEZS-108 happens to be in a Phase 2 trial in advanced advanced and ovarian endometrial tumor in Europe.Alere announces cash dividend of $3.00 per share on its Series B Convertible Perpetual Preferred Stock Alere Inc. , a global leader in fast diagnostics, today provides declared a money dividend of $3.00 per share on its Series B Convertible Perpetual Preferred Stock . The dividend is payable on July 15, 2015 to holders of record of Series B stock at the close of business on July 1, 2015. Such payment covers the amount of all dividends accrued from April 1, through June 30 2015, 2015.A., GW's business partner in Germany, and the German National Association of Statutory MEDICAL HEALTH INSURANCE Funds .